Received Aug 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 332L4 | — |
with the adjuvant alone.; Inappropriate dose of vaccine administered; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 51-year-old male patient who received Herpes zoster (Shingrix) (batch number 332L4, expiry date 04-APR-2027) for prophylaxis. On 28-JUL-2025, the patient received Shingrix. On 28-JUL-2025, an unknown time after receiving Shingrix, the patient experienced inappropriate preparation of medication (Verbatim: with the adjuvant alone.) and inappropriate dose of vaccine administered (Verbatim: Inappropriate dose of vaccine administered). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 08-AUG-2025 Clinical supervisor called to ask about the specific timeframe or additional vaccine administration for a valid dose of Shingrix, since five patients were potentially administered (they were not sure) with the adjuvant alone, which led to an inappropriate preparation of medication and inappropriate dose of vaccine administered. No further information was provided. The vaccine administration facility was the same as primary reporter. This was 1 of 5 linked cases reported by the same reporter.; Sender's Comments: US-GSK-US2025103162:same reporter GSK-US2025103644:Same reporter US-GSK-US2025103164:same reporter US-GSK-US2025103636:Same reporter